Overview

Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)

Status:
Active, not recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if nivolumab alone or nivolumab in combination with either bevacizumab or ipilimumab can help control metastatic kidney cancer. The safety of these drug combinations will also be studied.

Phase:

N/A

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Bristol-Myers Squibb
High Impact Clinical Research Support Program

Treatments:

Antibodies
Antibodies, Monoclonal
Bevacizumab
Immunoglobulins
Nivolumab